Details for New Drug Application (NDA): 213298
✉ Email this page to a colleague
The generic ingredient in ROFLUMILAST is roflumilast. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the roflumilast profile page.
Summary for 213298
| Tradename: | ROFLUMILAST |
| Applicant: | Aurobindo Pharma Ltd |
| Ingredient: | roflumilast |
| Patents: | 0 |
Pharmacology for NDA: 213298
| Mechanism of Action | Phosphodiesterase 4 Inhibitors |
Suppliers and Packaging for NDA: 213298
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ROFLUMILAST | roflumilast | TABLET;ORAL | 213298 | ANDA | Aurobindo Pharma Limited | 59651-275 | 59651-275-30 | 30 TABLET in 1 BOTTLE (59651-275-30) |
| ROFLUMILAST | roflumilast | TABLET;ORAL | 213298 | ANDA | Aurobindo Pharma Limited | 59651-275 | 59651-275-90 | 90 TABLET in 1 BOTTLE (59651-275-90) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MCG | ||||
| Approval Date: | Apr 17, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 250MCG | ||||
| Approval Date: | Jan 31, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
